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ABSTRACT 
Iron deficiency is the most prevalent micronutrient deficiency, attributing to 
approximately 800 million individuals with anemia, worldwide. This nutrient deficiency is 
greatly attributed to consumption of high plant-based diets and foods that have low bioavailable 
iron. Challenges arise in iron fortification, as the most affordable and conventional iron 
compounds have low bioavailability, therefore efforts have been made towards finding an iron 
fortificant with high bioavailability. The objective of this research was to determine the iron 
absorption of an iron-enriched fungus, Aspergillus oryzae (ASP-p) and determine its 
effectiveness compared to current fortificants ferric pyrophosphate (FePP) and ferrous sulfate 
(FeSO4). Two, single-blinded cross-over studies were conducted using a dual-labelled isotope 
method in young female subjects. Results indicated a 2.3 fold higher absorption in ASP-p 
compare to FePP (P = 0.0001), whereas ASP-p reported significantly lower absorption (P = 
0.0001) than FeSO4. 
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CHAPTER 1. GENERAL INTRODUCTION 
 
Background 
Iron deficiency anemia (IDA) is the most prevalent micronutrient deficiency, affecting 
approximately 30% of the world’s population – primarily children and women of childbearing 
age (1). Despite astronomical advancements in agricultural practices, food technology and global 
distribution of resources, iron deficiency (ID) remains the greatest source of anemia (2). As a 
result from depleted iron stores, consequences of IDA include: cognitive impairment, decreased 
productivity, morbidity and mortality (3–5). Iron deficiency is often a result of low intake of total 
dietary iron or consumption of foods primarily containing low iron bioavailability (IBA) – 
characterized by the amount of iron absorbed and accessible to the body to support physiological 
functions (6). Iron absorption includes both heme and non-heme iron, whereby several dietary 
components such as ascorbic acid, meat, phytic acid, and polyphenols which influence the 
overall non-heme iron absorption in a given food (7,8).  
 Several strategies exist in addressing the global burden of IDA, such as supplementation, 
dietary modification and fortification programs. Of these, fortification is suggested the most cost 
effective strategy, however challenges remain in finding an acceptable iron fortificant (9,10). 
Iron compounds which employ the highest bioavailable iron, result in negative organoleptic 
properties when added to food. Whereas, foods fortified with iron compounds which don’t exert 
adverse sensory changes, are those with the lowest bioavailability (11,12).   
Establishing a widely consumed food is exceedingly important as IDA can only be 
addressed with consistent adequate iron intake. One of the most widely consumed condiments in 
Africa is chicken bouillon cubes (13). Ferric pyrophosphate (FePP) is the iron compound used in 
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fortification, however daily consumption only meets ~1% of daily requirements (14). Therefore 
this research was carried out to assess the iron absorption of a new fortificant – iron-enriched 
Aspergillus oryzae (ASP-p) – when fortified in chicken bouillon.  
    Objectives 
1. To determine if iron-enriched Aspergillus oryzae (ASP-p) achieved higher iron 
absorption than currently used ferric pyrophosphate in chicken bouillon 
2. To assess the relative biological value (RBV) of the ASP-p compared to the standard, 
ferrous sulfate in chicken bouillon.  
Thesis Organization 
This thesis contains four chapters including a general introduction, literature review, one 
manuscript and an overall summary. The manuscript is titled, “Iron Absorption From a Novel 
Iron-Enriched Fortificant in Young Female Subjects,” and was written in preparation for 
submission to the Journal of Nutrition. The research described in this manuscript examined the 
iron absorption from three iron fortificants when fortified in chicken bouillon. References 
throughout the thesis are formatted based on the Journal of Nutrition. References placed at the 
end of each chapter represent only that chapter’s content. This thesis concludes with a discussion 
and recommendations for future research stemming from our findings. 
 Author’s Roles 
In the course of my master’s degree, I worked primarily on the clinical human iron 
absorption study. I did all of the initial paperwork alongside my major professor, Manju Reddy 
in filing Institutional Review Board applications, modifications and updating all certifications of 
myself and those who would be helping with the research project. I also functioned in 
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maintaining appropriate documentation and security of our study data and ClinicalTrial.gov 
updates.  
The majority of my work is presented in Chapter 3 of this thesis, which includes the 
design and execution that I led as a graduate student under Dr. Reddy’s oversight. I recruited, 
interviewed and performed all ELISA analyses for the context of this study. In regards to the 
manuscript, I wrote the draft and Dr. Manju Reddy edited the manuscript as lead investigator on 
the project.  
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CHAPTER 2.  LITERATURE REVIEW 
Role of Iron in Human Health 
Iron is an essential nutrient that is vitally important for countless biological processes. Its 
primary role is in the structure and function of hemoglobin and myoglobin, which are iron-
containing oxygen transporters (1). Hemoglobin is present in red blood cells, facilitating oxygen 
transport throughout the body, whereas myoglobin is located in the muscle tissue to support 
oxygen diffusion. Iron is also necessary for hematopoiesis, synthesis of new red blood cells, 
occurring every 120 days (2,3) 
Iron has a prominent role in the function of redox enzymes, which are non-heme iron-
sulfur (Fe-S) proteins characterized by a ubiquitous Fe-S or cofactor (4). Proteins containing 
these Fe-S clusters include metalloproteins, a class of enzymes whose primary function is to 
conduct oxidation-reduction reactions, participate in electron transfer in the mitochondria, 
regulate gene expression and bind active sites to enhance enzyme activity (4). Iron-sulfur cluster 
biogenesis results in production of numerous enzymes, including cytochrome c reductase, 
hydrogenases, nitrogenases, succinate-coenzyme Q reductase, and others (5,6). One Fe-S 
dependent example is the enzyme aconitase; its function is the catalytic conversion of citrate to 
its isomer, isocitrate, which is an essential intermediate for the tricarboxylic acid cycle and the 
formation of energy products, NADH+ and FADH2 (7). Notably, various diseases are related to 
disruption of Fe-S clusters, such as Friedreich’s ataxia and sideroblastic anemia (7,8) which 
result in the accumulation of reactive oxygen species (ROS) that target iron chaperone proteins 
(9).  
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Iron Metabolism 
The functions of iron are dependent upon the total body iron stores since the utilization of 
iron by various tissues is a tightly organized and regulated process. The average adult contains a 
total of 3-5g of iron in the body (1). 
Hemoglobin requires approximately 
75% total body iron for its synthesis, 
whereas, 10-20% or 1 g represents the 
iron in the storage protein, ferritin, 
found in enterocytes, liver and heart 
(Figure 2.1) (1). The remaining 5-
15% is used for the aforementioned 
processes such as gene expression, 
oxidation-reduction, etc. Unlike most 
nutrients, there is no inherent 
excretory mechanism for iron, 
other than the iron that is lost 
from epithelial turnover (10,11). 
The 1-2 mg/d of absorbed iron is typically sufficient for the average adult, however it is 
estimated that approximately 50% of basal iron losses (0.5-1.5 mg Fe/d) is from menstruation in 
women (12,13). Additionally, an estimated permanent iron loss of during pregnancy is ~840 mg 
Fe, therefore the iron requirement during pregnancy is ~1,000 mg to support both mother and 
fetus (14,15). Likewise, there is an increased absolute iron requirement of 0.7-0.9 mg Fe/day (17) 
to support vital growth and development of a child in his or hers first 1000 days of life as shown 
Figure 2.1. Iron utilization among body tissues. Storage 
form of iron is in ferritin and most iron is used to support 
erythropoiesis. No primary physiological excretion 
method apart from epithelial turnover. Abbaspour et al (1)  
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in Table 2.1. Iron requirements not only depend on the metabolism of the individual, but the 
absorption of dietary iron.  
Iron Absorption 
Iron absorption is dependent upon the type of iron consumed from the diet. There are 
three physiological states of iron, listed from the highest to lowest level of absorption: heme iron, 
ferrous iron (Fe2+), and ferric iron (Fe3+). All three are predominantly absorbed at the site of the 
duodenum (trace amounts in the jejunum) of the small intestine (17). The level of absorption or 
overall iron bioavailability (IBA) is highly variable. From a dietary standpoint, an estimated 5 - 
35% of the iron we consume can be absorbed by the enterocytes (17). This range of absorption is 
in part due to the influence other nutrients (when concurrently consumed with iron) and the 
status of total body iron stores (18). Iron absorption is an intricately dynamic and controlled 
process as we conserve the iron we absorb through recycling mechanisms for iron reutilization 
by other tissues (19). 
Heme iron absorption 
Heme is a porphyrin compound consisting of a central Fe ion (Figure 2.2). Heme is 
found in animal products such as meat, fish and poultry 
(20) where Western diets contribute approximately 10-
15% of the total dietary iron sources (21). Heme iron 
absorption contains higher bioavailability compared to 
non-heme, since heme iron is influenced less by 
additional dietary components (22). Heme is taken up by 
an independent mechanism. The formerly proposed 
transporter for heme was named 
Figure 2.2 The structure of heme iron 
which is found in animal products. Iron 
is found within the porphyrin ring 
(Wikipedia image). 
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Table 2.1. Iron intake requirements for growth under the age of 18 years, median basal iron losses, menstrual losses in women, and 
total absolute iron requirements Joint FAO/WHO (16).   
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heme carrier protein 1 (HCP1), while more recently, it has been postulated that the heme is taken 
up by a proton-coupled folate transporter (PCFT); however both mechanisms are unclear (23–
25). After the heme is absorbed into the mucosal cell, it is broken down by heme-oxygenase 1 
(HO-1) enzyme thereby liberating iron from the porphyrin ring, where it enters the nonheme iron 
pool in the enterocytes (26). 
Non-heme iron absorption 
Dietary non-heme iron must be in the Fe2+ form prior to transportation from the lumen 
into the enterocyte (Figure 2.3) (27). This process reducing ferric iron to ferrous iron is achieved 
by the action of a reducing-like agent, ascorbic acid or more commonly by the brush border 
ferric reductase, duodenal cytochrome b (DCYTB) (27,28). The concentration of Fe2+ 
transported into the enterocyte is modulated by an enterocyte blocking effect, whereby the 
intracellular iron stores (ferritin) dictate the amount of iron that will be transported by the apical 
membrane-bound, proton-pump dependent, divalent metal ion transporter 1 (DMT1) (27,29). In 
addition to iron, the DMT1 transports other metals: cadmium, copper, zinc and manganese.        
             
 
 
Figure 2.3. Duodenal enterocytic uptake of dietary iron sources: 
nonheme and heme. DMT1 facilitates the uptake of reduced Fe3+ to 
Fe2+ by DCYTB from Hurrell et al (28). 
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Arredondo et al (30) demonstrated antagonistic effects Fe, Cu, and Zn have on each 
other, suggesting there is competitive uptake among these minerals. Results indicated that 
disproportionate levels of the respective minerals was driven by saturation, whereby when more 
Cu was presented to the cell, there was a dampening effect on Fe and Zn uptake (29,30).  
 
Iron Regulation and Homeostasis 
Storage and Release 
Following intestinal uptake, liberated heme-bound-Fe and non-heme Fe transported 
through the apical membrane enter the labile iron pool (31). This common pool serves as a 
crossroads between the cytosolic signaling of iron regulatory proteins and the shunting of iron 
into storage within a ferritin molecule, which can hold ~4500 Fe3+ iron atoms (32,33). Ferritin is 
an acute phase protein which is directly influenced by hepcidin and closely associated with c-
reactive protein (CRP), two inflammatory markers affecting iron homeostasis (34,35). Under 
normal conditions the iron which is not used intracellularly or stored will enter into circulation. 
This efflux of the iron from the enterocyte into circulation is mediated by the basolateral 
transporter, ferroportin 1 (FPN1) along with the ferroxidase hephaestin, to oxidize Fe2+ to Fe3+ 
(36). After iron is released from the intestine as Fe3+, it is sequestered by transferrin (Tf), a 
circulatory glycoprotein chaperone to be carried in the blood. Various tissues will then take up 
iron through a receptor-mediated endocytosis pathway by the transferrin receptor (Tfr) (37). The 
Tfr has a high affinity for Tf, allowing for the clathrin-mediated endocytosis of holo-Tf-Tfr into 
the endosomes (37). An endosome’s acidic pH results in the dissociation of the complex, iron is 
released via DMT1 for functional use. Tfr then relocates to the membrane after its dissociation 
with Tf (38).  
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Regulation of iron mobilization 
There are distinct differences in iron absorption when comparing insufficient versus 
sufficient conditions as the body has the capacity to sense and regulate these factors. During an 
iron-deplete condition,  iron absorption into the mucosal cells is upregulated (39). Conversely, 
when plasma iron concentrations are low, levels can be restored through the release of iron from 
ferritin storage protein in reticuloendothelial macrophages, enterocytes and hepatocytes (10). 
This release of iron into circulation is through FPN1, after which it is oxidized by the hephaestin 
homologue ceruloplasmin (40).  This process of Fe2+ efflux is crucial in maintaining iron 
homeostasis in response to low serum Fe. Transferrin receptor expression is regulated at the 
transcriptional level by an iron-responsive element-binding protein (IRP) (41). Under 
circumstances of low circulating serum Fe, in the 3’ untranslated region of mRNA, IRP binds to 
a stem loop structure, known as the iron response element (IRE) (42). When IRP is bound to the 
IRE, the mRNA is stabilized, allowing for increased translation to upregulate Tfr synthesis (43). 
In contrast, the IRP when bound to the IRE on the 5’ end of the mRNA inhibits the translation of 
ferritin, thereby reducing iron storage. In iron excess condition, IRP is released from IRE and Tfr 
mRNA is degraded and the IRP is removed, allowing the translation of ferritin (42).   
This homeostatic process can be disrupted when a large bolus of Fe2+ iron is absorbed, or 
when the FPN1 function is compromised. When a bolus of highly soluble iron (Fe2+) is absorbed 
into the enterocyte, this floods the system, overwhelming the Tf, resulting in unbound Fe2+ in 
circulation, otherwise known as non-transferrin bound iron (NTBI) (44). This NTBI can induce 
free radical generation through the Fenton reaction, generating hydroxyl radicals (45).  
Under conditions of systemic inflammation, upregulation of hepcidin, a key regulator in 
iron homeostasis, acts on the basal lateral transporter, FPN1, resulting in the internalization of 
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FPN1, causing decreased iron absorption (Figure 2.4) (46). Hepcidin regulates iron release into 
circulation at three locations: 1) duodenal iron absorption 2) macrophages’ recycled iron from 
senescent and damaged red blood cells 3) hepatocytes’ storage (47). Recent studies have 
examined the increased hepcidin levels due to NTBI (48,49). Moretti et al. conducted a dose-
dependent study investigating the absorptive outcomes when subjects were administered FeSO4 
doses of 40, 60, 80, 160 and 240 mg daily. In their study, they observed a significant increase in 
circulating hepcidin and when subjects were given doses ≥60 mg FeSO4, there was a 35-45% 
observed decrease in iron absorption (50).  
         
Iron Deficiency Anemia 
 There are many factors that govern the utilization of iron in the body. When there is not 
enough iron ingested in the diet or excess iron losses, this leads to iron deficient conditions. 
Inflammation is also known to cause anemia, apart from iron deficiency, due to the trapping of 
Figure 2.4. (A) Increased hepcidin expression by the liver, leading to internalization of FPN1, 
results in low plasma Fe levels due to iron accumulation inside enterocyte. (B) Normal hepcidin 
levels, regulating the iron exported into the plasma. (C) Hemochromatosis, or iron overload from 
insufficient hepcidin levels. No FPN1 internalization, therefore plasma Fe levels continue to 
increase. Domenico et al. (46).  
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iron in storage in the presence of hepcidin (34). During inflammation, the body’s inability to 
mobilize the iron in storage, which may lead to the inadequate incorporation into hemoglobin, 
otherwise defined as iron deficiency anemia (IDA) (51).  
Prevalence 
According to the 2011 WHO report, over 1.6 billion individuals globally are afflicted 
with anemia and of these, it is estimated that 50% is attributed to iron deficiency (ID) (52). Iron 
deficiency anemia is the only micronutrient disorder that is commonly seen in both industrialized 
and developing countries. Reports indicate a 38% prevalence of IDA in pregnant women aged 
15-49 years. Additionally, IDA is common among children, whereby 18.1% of those <5 years of 
age are classified anemic (53). These staggering numbers sparked the introduction of the “WHO 
2025 Global Targets for maternal, infant and child nutrition”. One specific aim was “targeted to 
support the Global Health Assembly initiative towards a 50% reduction of anemia in women of 
reproductive age by 2025” (50). 
Consequences 
Iron deficiency (ID) results in the reduced capacity to generate new red blood cells, and 
ultimately hemoglobin, causing IDA. Several ramifications stem from ID, especially during fetal 
and infant growth and development. A lack of iron attributes to slow neurodevelopment, causing 
behavioral and cognitive impairment (54,55). Other adverse outcomes, such as fatigue, decreased 
motor maturation, increased risk for preeclampsia and morbidity and mortality manifest from 
IDA (56,57). These implications further impose economic consequences with an estimated 
median total loss of $16.78 per capita or 4.05% of gross domestic product due to both cognitive 
impairment and decreased productivity (58,59).  
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Stages of iron deficiency 
Iron deficiency anemia (IDA) is a gradual and progressive nutritional condition as a 
result of multiple factors including inadequate iron intake, gastrointestinal related blood loss, 
inflammation, as well as infections (51,60). This progression of iron depletion to IDA is 
subdivided into three clinical stages – pre-latent, latent and IDA – with each stage containing 
various consequential outcomes (61). All three stages are defined by overlapping iron status 
indicators and diagnostic criteria outlined in Table 2.2. The first, or pre-latent stage of iron 
deficiency, reflects suboptimal/depleted iron stores. Clinical assessments often use serum ferritin 
(SF) as the primary indicator of iron deficiency (62), however SF is an acute phase protein, 
whereby low concentrations may be masked by inflammation-induced hepcidin (63). 
The second stage is measured by total iron binding capacity (TIBC), whereby long-term 
inadequate iron intake leads to a state of negative iron balance, referred to as iron deficient 
erythropoiesis (62). This stage is characterized by increasingly exhausted SF levels (<15 µg/L), 
elevated TIBC (>400 ug/dL) and serum transferrin receptor of >8.5 mg/L. Collectively, TIBC 
and serum iron is used for calculating percent saturation (TIBC/serum iron x 100). Transferrin 
saturation and red blood cell protoporphyrin (<70 ug/dL) decrease in stage 2, with normal Hb 
(>12 g/dL) (62).  
The third stage is defined as IDA, whereby iron stores are diminished to the extent there 
is insufficient iron available for hematopoiesis and Hb maintenance. The clinical diagnosis for 
IDA is Hb <12 g/dL in females and <13 g/dL in males. Mean corpuscular volume (MCV) may 
be an indicator for IDA, but it is also affected by other nutrients causing microcytic or 
megaloblastic anemia (62).  
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These clinical parameters are good for distinguishing one stage from another, but there 
should be careful considerations when assessing these markers. For instance, more recently, the 
sTfR/log(ferritin) diagnostic ratio has shown to be more specific when classifying true IDA (64). 
Generally, clinicians often rely on multiple iron assessments to distinguish true ID from 
inflammatory or acutely-induced deficiency (63).  
 
Table 2.2. Clinical iron status indicators for the three stages of iron deficiency.  
Stages of Iron Deficiency Clinical Parameters Diagnostic Range 
Storage Iron Depletion (prelatent) Marrow iron stores Absent 
 Serum ferritin (ug/L) <20 
Iron Deficient Erythropoiesis 
(latent) 
Serum iron (ug/dL) <10 
 TIBC (ug/dL) >400 
 Transferrin saturation (%) <16 
 sTFR (mg/L) >8.5 
 RBC protoporphyrin (ug/dL) <70  
Iron Deficiency Anemia Hemoglobin (g/dL) 
      Females 
      Males 
 
<12 
<13 
 MCV <80 
*Adapted from WHO, Worwood 1997 (61). 
 
Iron Bioavailability 
 Iron bioavailability (IBA) is described as the amount of absorbable iron from dietary 
components that is available for the physiological processes which require iron (65). Several 
dietary components, such as ascorbic acid (AA) and animal products like meat, fish and poultry 
(MFP), play a significant role in determining the fate of the iron bioavailability in a given food 
(66). On the other hand, dietary inhibitors, or antinutritive factors, are those which tightly bind 
iron or cause the inhibition of its absorption; these most often include phytic acid from bran and 
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seeds (67), and competitive inhibitors like polyphenols found in coffee, tea and beans (68). 
While individual effect of each factor is well studied, understanding their effects in a mixed meal 
is complex (69).   
Dietary enhancers 
 Ascorbic acid is a reducing agent of non-heme iron, which is a potent enhancer of iron 
absorption (70). It has the capacity to augment the iron absorption within complex food matrices, 
overcoming the inhibitory effects of chelating compounds such as phytic acid, polyphenols and 
calcium (71). In a single meal study, AA did notably increase iron absorption, but its effect is 
modest in a whole meal (70); this revealed AA shows greater effect on nonheme iron absorption 
when examined in a single meal rather than whole diet.  
Meat, when concomitantly consumed iron containing foods, has demonstrated to increase 
non-heme iron absorption in plant-based foods, otherwise known as the, “meat factor” (72). The 
enhancing effect has been suggested to be due to the ability of maintaining iron in its soluble 
form during digestion (73). Several studies have examined the meat effect on non-heme iron 
absorption and concluded there are enhancing properties of meat when added to meals with low 
IBA (74). Engelmann et al (75) added meat to an infant meal and observed a 15% RBV 
compared to 9.9% with no added meat. Reddy et al found an increase from 4.8 to 6.5% in 
nonheme iron absorption when comparing individuals who consume no meat versus a high-meat 
diet (76).  
Dietary inhibitors  
 Phytic acid is predominantly found in nuts, legumes and seeds. Its cyclic acid structure 
has a high affinity for minerals, especially iron, making iron almost completely unabsorbable. 
When phytates were removed from cereal porridge, iron absorption of native iron showed to be 
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increased significantly (77), demonstrating the strong inhibitory effects PA has in cereal grains. 
A report by Joy et al (78) determined in African, the mean supply of phytate was 2770 mg per 
capita each day, suggesting African (where ID is common) diets contain high amounts of these 
iron inhibitors. Although phytate is known to have an impact on iron absorption, Armah et al 
observed a decreased inhibition of phytate on nonheme iron absorption when persons regularly 
consumed high phytate diets (79). 
Polyphenols are commonly found in pulses and cereals with highest concentrations 
generally reported in coffee and tea (80). PP have antinutritive properties since they can bind 
iron in the gut, dampening intestinal Fe absorption (81). Many different types and amounts 
(grams) of PP are found in various foods. Black tea PP are known to have more of an inhibitory 
effect than PP in coffee (82). Herbal teas and cocoa are also known to inhibit absorption but less 
than black tea; an inverse relationship has been reported with PP content and Fe absorption 
(83,84). 
Several studies have investigated how IBA of native or elemental iron can be dampened 
(85) or increased (86) depending on the matrix with which it’s consumed. Moreover, when iron 
is administered in a liquid rather than a semi-solid or solid meal, there is a disproportionately 
higher iron absorption when consumed with liquid (69). Therefore, careful consideration must be 
taken when measuring the relative biological value (RBV) of a given iron compound. 
 
Methods of Assessment for Iron Absorption/Bioavailability 
 Due to the nature of iron’s absorption and the complex mechanisms by which it can be 
absorbed, there are several methods used in order to measure the bioavailability of various 
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dietary iron sources. As mentioned, iron absorption is manipulated by many factors, both 
positive and negative, so it is important to consider which methods are utilized. 
In vitro solubility/dialyzability 
 In vitro methods are often used to determine the iron solubility of foods, because they are 
convenient and inexpensive. This methodology uses a controlled environment to mimic the 
human gastrointestinal digestion, whereby the food is subjected to brush border enzyme digest. 
The non-heme iron released during in vitro digestion is then measured using a colorimetric assay 
for total soluble iron content (87). A more traditional iron solubility method is the assessment of 
dialyzable iron (88,89). In vitro dialyzability is a two-step digestion whereby contents are 
fractionized in a dialysis bag with low molecular weight coefficient and measured dialyzable Fe 
as an index of IBA (90,91). Limitations of the solubility/dialyzability are that they are not a 
strong indicator of IBA, rather they are useful as a secondary measure to assess concentration of 
iron chelators prior to mucosal uptake (89).  
Cell culture model 
  To mimic the human physiological conditions, in vitro solubility/dialyzability tests are 
commonly carried out further using a Caco-2 cell model, as the rat model is shown to be less 
sensitive to dietary factors (92). Caco-2 are human epithelial colorectal adenocarcinoma cells 
which spontaneously differentiate into epithelial enterocytes forming a brush border and 
corresponding digestive enzymes (93). These cells are grown under conditions mimicking human 
body temperature of 37C and 5% CO2 for suitable growth. Bioavailability is then determined 
following treatment and % RBV is measured by using ferritin as a surrogate for IBA or via 
inductively coupled plasma spectrometry (ICP) (94). IBA of Caco-2 cells has been strongly 
correlated with human absorption (95). It should be noted there are limitations in using the Caco-
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2 cell culture model, because the regulation of hepcidin is absent. New models attempt to 
integrate hepcidin’s role by combining Caco-2 with the HepG2 cell model (90).   
Animal models 
 To date, the hemoglobin depletion-repletion model in rats is the most standard method to 
assess iron absorption and was established by Association of Official Analytical Chemists 
(AOAC) (96,97). Predominantly rat species have been examined to determine responsiveness to 
iron repletion following iron depletion. Wistar rats were determined to be the best models when 
three rat species were compared (98,99). Pigs can be used for the same method but they are 
expensive (100). 
 The hemoglobin depletion-repletion assay (101) utilizing the Wistar animal model 
includes rats fed an iron-deficient (2.5 mg/kg or 5 mg/kg elemental Fe) diet for approximately 
25-35 days to deplete hemoglobin levels prior to iron repletion. Iron repletion includes any 
experimental dietary iron being tested – both supplemental and dietary (96). Following the 
intervention, hemoglobin concentrations are determined and assessed among treatment and 
control (FeSO4) groups to estimate two values: 1) relative biological values (RBV %) against 
FeSO4 is 100% 2) Hb regeneration efficiency (HRE%) ratio to determine the IBA based upon the 
improvement in Hb concentration relative to the amount consumed.  
Human studies 
 Human studies give direct measure of absorption, though they are expensive to conduct. 
Three common techniques are used to assess iron absorption: area under the curve (AUC), 
radioisotopes and stable isotopes. Serum iron curves can be used to measure the absorption from 
iron doses as low as 5-20 mg Fe (79,102). In this method, subjects consume an iron supplement 
or meal containing the iron treatment of interest. Following ingestion, blood samples are taken 
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every 30 minutes and plotted on a curve starting with baseline measures. The area under the 
curve (AUC) is then used to calculate the total iron absorbed in that timeframe. Benefit of the 
AUC method is it is inexpensive relative to isotope studies, as well as utilization to assess 
kinetics of Fe release. The limitation of AUC method is it takes extended time to get serum Fe 
levels to reach back to baseline, which can be hard on the subjects.  
 Tracer methodology in human research through radioisotopes is a powerful tool to assess 
how the body acquires the micronutrients following digestion and absorption. Radioisotopes, 
55Fe and 59Fe are used both through intrinsic and extrinsic labelling. Due to the unconventional, 
cumbersome nature of intrinsic labelling in iron absorption studies, Cook et al (103) compared 
iron absorption with intrinsic and extrinsic methods, showing no significant differences between 
absorption of the two labelled iron methods, proposing use of extrinsic-labelling in the later 
years. Limitations are exposing humans to radio isotopes, though it is never more than a single 
chest x-ray dose.   
 Stable isotopes are the preferred methodology as they are safer than radioisotopes, 
however they are exceedingly more expensive. In nature, our human body contains four main 
iron isotopes with differing abundance (54Fe, 56Fe, 57Fe and 58Fe). Stable iron isotopes for use in 
human metabolic studies, are often 57Fe and 58Fe since the natural abundance is the lowest 
among the naturally occurring isotopes, 2.1% and 0.28% iron, respectively. Since these isotopes 
are already prevalent in our bodies, analysis requires a sensitive instrument to detect the 
enrichment. Similar to radio isotope studies, two meals with two isotopes are fed to the same 
subject to reduce inter-subject variability (103,104). 
Iron incorporation into red blood cells or iron content of Hb is used to assess stable 
isotope enrichment in the blood. Following consumption of the total isotope dose, 14 days is 
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allowed for the incorporation of the isotope into the hemoglobin. Iron is then separated by use of 
anion exchange chromatography (105). Following, iron ratios (baseline enrichment to 14 d post-
dosing) can be measured through mass spectrometry (104). Fractional iron absorptions are 
calculated based on the assumption that 80% of the iron is incorporated into the hemoglobin after 
estimating total blood volume by height and weight of subjects (Figure 2.5) (107,108,109).  
 
 
 
 
Although there are several methods to accurately determine iron absorption in humans, 
long-term efficacy studies are needed to observe changes in iron status as measured by many 
status indicators accounting for confounding factors. Trials determining the efficacy of an iron 
intervention are conducted in a large, controlled environment typically over the course of a 
several months to assess its effectiveness on treating an ailment. Efficacy studies are expensive 
to conduct, take a lot of coordination among individuals as well as demand a large number of 
subjects, in contrast to the small number required for isotope studies (109). They are necessary 
however, to assess the impact on a larger population. Several efficacy studies have helped 
advance the field of finding a suitable, effective iron treatment for various populations on 
improving the iron status (110–112).  
Figure 2.5. Isotope enrichment calculations where Rt57:56 and Rt58:56 are 
the enriched isotope ratios at time t (days after final dose). Fe(circ) is the total 
circulating Fe on t. A57 and A58 are the natural abundances (2.1) and (0.28). 
These are measured against baseline indicated by R0. From Kastenmayer et 
al. (108). 
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Interventions to Treat Iron Deficiency Anemia 
To address ID and IDA, there are challenges in finding a suitable, sustainable and 
effective intervention. There are barriers to finding an appropriate treatment since cost, 
accessibility and distribution all play a vital role in iron outcomes. It is well established that not 
all forms of iron treatment are suitable for every population. The economics, comorbidities, 
disease and cultural aspects are driving forces for designing and establishing effective 
interventions for IDA. Currently, there are four main intervention strategies used to help 
ameliorate the incidence of IDA including: supplementation, home fortification, biofortification, 
dietary modifications and food fortification. All come with their own benefits and drawbacks 
which are assessed and summarized below.  
Supplementation 
Iron supplementation is the most frequently used strategy because of its targeted 
approach in providing high doses of iron in a convenient and direct form (113). Frequently 
associated consequences of IDA have been suggested to be adequately addressed through 
supplementation due to its cost-effectiveness. Studies have demonstrated improvements in 
mental performance, fine motor movements, as well as decreased fatigue and anxiety outcomes 
in iron deficient individuals given daily iron supplements (114,115). Among pregnant women in 
China with low iron stores taking Fe supplements, Zhao et al (116) found significantly higher 
maternal hemoglobin levels, reduced iron deficiency anemia, and greater concentrations of 
umbilical cord serum iron than those women not taking iron supplements.  
Several iron supplements, such as ferrous sulfate heptahydrate, ferrous gluconate, and 
ferrous fumarate have been identified as primary supplemental treatments for iron deficiency 
anemia (117). Recently, the WHO set recommendations for daily doses of these compounds 
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ranging from 30-60 mg elemental iron from FeSO4, ferrous gluconate and fumarate, in pregnant 
women (118). The WHO switched from daily to intermittent administration of iron supplements 
particularly in malaria endemic areas (50). This was based upon the understanding that there is a 
mucosal blocking effect of iron, dampening the ability for the release of iron from duodenum 
into the plasma (99,119). Differences between daily and intermittent iron administration were 
analyzed and such findings showed both weekly and daily supplementation were efficacious 
(69,120). A recent study by (50) suggests 48 hours between iron supplements, rather than 5 to 6 
days, provides adequate time for recovery of the enterocytes from down regulating hepcidin and 
other hormonal factors. Although daily administration improves iron status, tri-weekly intake of 
iron supplements may improve compliance by reducing associated side effects, systemic 
inflammation and ultimately provide better long term outcomes in iron status indicators 
(50,121,122). 
Effectiveness of iron supplementation has confounding factors such as limited 
distribution to developing nations and non-compliance due to adverse effects from high iron 
doses to the gastrointestinal tract (123). Aside from oral iron causing gastrointestinal distress, 
bloating and constipation, a high bolus of an iron supplement has been shown to cause NTBI, 
further exacerbating certain disease conditions (124). For instance, iron is an essential nutrient 
for the malaria pathogen, Plasmodium falciparum (125). It is well established that the non-
transferrin bound iron in the plasma is a primary nutrient for the pathogen’s integrity, 
contributing to the parasitic growth of the Plasmodium, causing increased exposure of the 
pathogen in circulation of the brain and intestines (126). Therefore, the WHO stated iron 
supplements should be provided intermittently alongside other strategies to control malaria to 
prevent those with malaria from dying of excess iron supplements (127,128).  
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Home Fortification of Micronutrient Powders  
Micronutrient powders (MNPs) are otherwise recognized as at-home or point-of-use 
fortification programs, first established after the creation of MNP Sprinkles by Schauer and his 
colleagues in 2003 (129). Each MNP sachet provides a single-serving containing 15 vitamin and 
minerals and was designed to be “sprinkled” on semi-solid food to serve as an efficacious 
strategy to address concomitant nutritional deficiencies (130,131). The novelty of these Sprinkles 
pertains to the microencapsulation of the iron in the form of ferrous (III) fumarate to provide 
protection from processing, storage and competitive absorption with other minerals such as zinc 
(132–134).  
Since 2003 when MNP programs were implemented, many countries have shown 
improvements in stunted growth and overall health. In Nepal, refugee children were given daily 
Vita-Mix-It containing the recommended nutrient intake of 16 vitamins and minerals from age 1-
3 y (135). Reports from the 18 month intervention indicated no significant reduction in anemia, 
however parents did indicate a significant reduction in diarrhea, and vomiting as well as 
increased energy levels in their children (135). Additional long-term MNP programs have 
attributed their non-significant improvements in iron status to the unacceptability and non-
compliance of the Sprinkles due to reported fear of artificial and synthetic ingredients and a 
preference to nurture their children with culturally familiar foods (136,137).  
Micronutrient powder programs have also been explored in pregnant women. Lower 
doses of iron (2.5mg) combined with ascorbic acid and exogenous phytase consumption reduced 
iron deficiency from 75% to 18.9% following 6 months (138). Low iron dose in presence of 
exogenous phytase demonstrated to be efficacious in reducing IDA, however residual concerns 
regarding the bitter taste of the MNP when added to rice is a foreseeable problem (131). Overall, 
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MNP programs have been successful, however they are expensive to implement and only reach 
specific countries who are participating.  
Biofortification  
Iron biofortification is an agricultural practice in which the nutrients of staple crops are 
improved by modes of conventional plant breeding technology. Foods most commonly 
biofortified with iron are cassava, rice and grains, as well as beans and legumes (139). These are 
often native staple crops in areas with low accessibility to iron-rich foods and are commonly 
multi-bred for various nutrients such as vitamin A carotenoids, zinc, and iodine (140). 
Biofortification of iron can be achieved through several strategies: 1) decreasing antinutritive 
factors like polyphenols and phytates, 2) increasing the concentration of iron within the 
respective crop, 3) increasing nutrient iron enhancers, such as ascorbic acid (141). Following a 
nine month feeding trail of biofortified (1.79 mg/d) and unfortified (0.37 mg/d) rice in Filipino 
women, there were observed increases in serum ferritin stores, but not hemoglobin in only the 
nonanemic group, suggesting this isn’t a sustainable/effective strategy for addressing IDA (142). 
Recent reviews highlight the efficacy of iron biofortification, showing positive improvement for 
the overall nutrition and health outcomes of a given population (143,144). However, the upfront 
investment and time in cross-breeding crops for high quality nutrients becomes costly to ensure 
the iron is deposited in the seed of the crop rather than trapped in the inedible portions like roots 
and leaves.  
Dietary Modifications  
There exist inherent limitations when attempting to modify the foods people regularly 
consume as ingredient variety is typically not an option in most developing countries making 
dietary modifications difficult to implement. A recent review discussed ways to improve the iron 
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status of children and women of child-bearing age in affluent countries (145). Results indicated 
most women were meeting their daily requirements for iron, however this was achieved by high 
consumption of heme-iron containing foods like meat. Since meat is rarely consumed in most 
developing countries, modifying the cultural diets and behaviors of people is not appropriate 
where adequate high iron foods are not accessible nor affordable (145).  
Fortification  
Iron fortification has been described as the most cost-effective, sustainable strategy of the 
primary approaches (146). Utilizing micronutrient fortification of foods allows diverse subsets of 
populations to be reached. By employing local, commercialized products as the vehicle for iron 
fortification, there is a greater dispersion of iron fortificants to all populations irrespective of 
location, culture, economic class, and social dependencies (58).  
Iron fortification of regularly consumed condiments can aid in the amelioration of this 
widespread deficiency. However, established barriers exist in the formulation of these vehicles 
(147). Iron demands considerable attention when being added to food, as it can react with the 
food matrix, resulting in organoleptic problems such as rancidity, alterations in color, shelf-life 
stability, and consumer acceptability (148,149). The highest bioavailable iron sources are the 
most soluble and thus cause sensory problems in the food, whereas the iron compounds which do 
not cause adverse sensory outcomes are typically of the lowest bioavailable iron sources (110).  
Staple foods such as wheat flour, rice, milk and infant formulas have been long used for 
iron fortification (150–152). Many countries have implemented programs focused around 
fortifying staple foods with iron, however there are drawbacks, such that certain members of the 
population may not regularly consume these staple foods or have access to them. Unless these 
staple foods are fortified with multiple nutrients, regular consumption may also impose 
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deficiencies of other micronutrients. There also exist technological problems in fortifying foods 
with iron, as there are barriers in the amount of iron a given food may be able to tolerate in 
relation to its sensory characteristics. Therefore, there is no silver bullet when it comes to finding 
an iron intervention strategy, thus by combining strategies, there may be added benefits.  
The implementation of iron fortification in condiments and commonly consumed food 
vehicles has shown to be effective as this strategy focuses on fortifying regularly consumed 
condiments, eliminating concern of adherence and affordability (153). A recent meta-analysis 
analyzed the comparison of iron status outcomes from iron fortified condiments compared to 
noodles (154). The review found a significant increase in hemoglobin of adults and children 
consuming iron-enriched/fortified condiments in comparison to noodles, 0.74g/dL Hb and 
0.3g/dL Hb, respectively (154).  
Condiments and Bouillon Spices 
Despite the advanced research in various iron interventions and multiple governmental 
programs established, there are still technical challenges when attempting to fortify foods with 
iron. Since iron is highly reactive and readily undergoes oxidation and reduction reactions, 
industries have introduced more conventional approaches such as adding iron to condiments and 
spices to provide a matrix to support the iron and provide soluble iron carriers (155,156). For 
instance, insoluble iron compounds are best suited for dry spices, whereas soluble iron 
compounds which notably turn food green, have been integrated into soy sauce to appear more 
inert (155).  
Bouillon cubes are most commonly consumed in the addition to soups, stews, curries and 
sauces in place of common spices such as salt and paper. They contain dehydrated stock in the 
forms of either vegetable, chicken, seafood, or beef as well as salt, vegetable fat, flavor 
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enhancers (monosodium glutamate) and spices to be sprinkled on top of any dish (mainly rice) 
and boiled in stews. Due to their wide distribution and frequent consumption, alongside their 
affordable cost and accessibility, bouillon cubes are an appropriate vehicle for iron fortification, 
especially in areas of highly prevalent iron deficiency, such as West and Central regions of 
Africa (157).   
Several well-established transnational companies, like Unilever, Nestle’ and GB foods 
have designed multiple-fortified and commercialized chicken bouillon cubes with vitamin A, 
iodine and iron (158,159). Though not all chicken bouillon cubes are micronutrient fortified, the 
ones currently distributed to regions of Africa are brand named including Maggi®, Knorr®/ 
Royco® and Jumbo® (156,160). In 2015, Nestle reported an estimated 44 billion iron fortified 
chicken bouillon cubes were dispersed. In places such as Nigeria, chicken bouillon cube sales 
reaches a staggering 80 million cubes sold each day.  
In addition to the convenience and acceptability of fortifying chicken bouillon cubes, 
their vast, frequent consumption is what makes them a promising IDA intervention strategy. A 
summarized study by Hess and colleagues, examined survey outcomes from 12 sub-Saharan 
African countries’ using the Fortification Rapid Assessment Tool to estimate the consumption of 
fortified foods (157). The survey focused on the consumption patterns of four commonly 
consumed foods (wheat flour, sugar, vegetable oil and chicken bouillon cubes) in hopes to 
determine the best national food fortification programs to expand. Findings from the study 
reported a range from 79-99% of women in those surveyed countries consumed bouillon cubes 
within that week. Women in Cameroon had the highest chicken bouillon cube consumption with 
reporting mean consumption of 13.8 times per week (161). On average among the four surveyed 
nation, consumption ranged from approximately 1.5-4 g/day (161).  
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Iron Fortificants 
Many iron fortificants are available, all with varying levels of iron bioavailability, cost 
and solubility. Finding a single iron compound that is cost-effective and easy to fortify foods 
with has been the challenge in this realm of research. Food vehicles themselves have functional 
groups which interact differently depending on the iron compound with which they are fortified, 
therefore finding the appropriate iron compound to fortify a vehicle of interest is essential.  
Currently, there are a wide array of iron compounds being used for fortification, and can 
be categorized into: 1) water soluble; 2) acid-soluble; 3) insoluble; and 4) encapsulated. Most 
commonly used fortificants have been described and adequately classified based on their cost, 
bioavailability and solubility in solutions (Table 2.3). 
Water soluble iron compounds  
Water soluble iron compounds are highly bioavailable, owing to their high solubility.  
However, being soluble results in interactions with the food matrix, resulting in negative 
organoleptic outcomes (162).  
Ferrous sulfate 
Ferrous sulfate is used for comparison in both supplementation and fortification as it 
contains 100% RBV. FeSO4 has two forms in fortification, both heptahydrate (20% Fe) and dried 
(33% Fe). Because of its high solubility, FeSO4 is functional in fortifying dry foods with little 
moisture, such as pastas, low extraction wheat flour, milk powder and dried milk-based infant 
formulas (163). A 35-week study examined ferrous sulfate’s efficacy on improving iron status in 
Thai women given fortified wheat-based snacks containing 12 mg Fe/d 6 out of the 7d/wk (164). 
The study resulted in significant improvement of iron status, indicated by total body iron stores 
increasing from 1.5 to 5.3 mg/kg body weight and an 80% reduction of women with iron 
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deficiency. Studies have shown ferrous sulfate fortified in milk based infant formula is effective 
in reducing ID in infants (165).  
Principally, FeSO4 is the most frequently used iron compound due to its inexpensive cost. 
Though it is cheap, there are limitations to its use in fortification. For instance, it has been shown 
to cause unacceptable organoleptic problems including: lipid oxidation, rancidity, and vitamin 
oxidation ultimately provoking off flavors and colors in the foods like rice, soups and milk 
(21,166).   
Ferrous bisglycinate 
Ferrous bisglycinate has shown high RBV but is rapidly oxidized to Fe3+ in the presence 
of water. Addition of citric acid (redox stabilizing iron) prevents iron oxidation, eliminating off-
color effects of iron. Moreover, this redox-stabilized FBG when administered to women and 
children, has shown to improve iron levels (167,168).  
Acid Soluble Iron Compounds 
Ferrous fumarate 
Ferrous fumarate without capsulation is soluble only in dilute acid. It is a dark red, fine 
powder which contains comparable RBV to ferrous sulfate due to its solubility in the gastric 
juice (163).  Several efficacy studies have demonstrated the effectiveness of ferrous fumarate in 
enhancing iron stores. Using a hemoglobin repletion study, Mehansho et al (169) examined the 
hemoglobin differences and RBV among FeSO4, encapsulated ferrous fumarate and ferrous 
fumarate without the encapsulation and concluded there were significant hemoglobin gain in the 
rats, however the two forms of ferrous fumarate were not significantly different from one 
another. Additionally, the RBV for the encapsulated and unencapsulated ferrous fumarate was 98 
and 107, respectively (169). Since the iron in the form of ferrous fumarate is insoluble in water, 
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it is used in reconstituted dry infant cereals as source of high bioavailable iron, as reported in 
comparison to FeSO4 (170). Ziegler and his colleagues assessed the efficacy of both ferrous 
fumarate (52.5 mg Fe/100g dw) and electrolytic iron (54.5 mg Fe/100g dw) fortified dry infant 
cereal on the ability to maintain iron status and prevent ID onset with daily consumption in 4-9 
month old infants (170). Daily ferrous fumarate showed when consumed daily, they were 
effective in maintaining iron status during exponential growth period (170).   
Insoluble iron compounds 
Elemental iron 
Elemental iron is the most prevalently utilized source of iron in fortifying commercial 
food products because of its significantly low cost and inertness in the food (171). While the 
former is true, the bioavailability of elemental iron compounds is so low that despite large 
quantities fortified in foods, the absorbable dietary amount of elemental iron is negligible. 
Therefore, companies have manipulated the particle size (<45 microns or 325 mesh) and surface 
area in an aim to increase its bioavailability, which has been modestly successful, however the 
IBA remains unresolved because of the vast differences in manufacturing (172) The different 
forms of elemental iron include: H-reduced, atomized, CO-reduced, electrolytic and carbonyl – 
all containing vastly different RBVs as reported in Table 2.3. Human bioavailability studies 
have evaluated the differences among these commercial iron sources. Walter et al. (2014) 
reported bioavailability of H2-reduced elemental iron of 62% RBV when fortified in white bread 
(173); electrolytic Glidden A-131 iron showed a RBV of 50% compared to FeSO4 when fortified 
in bread rolls (174); following a feeding study of doubly-labelled wheat rolls containing carbonyl 
iron (55Fe) and native iron (59FeCl3), reported RBV percentages ranged from 5-20% depending 
on the food matrix it was consumed with (14).  
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Ferric pyrophosphate 
Ferric pyrophosphate (FePP) has an off-white color, which is favorable in commercial 
fortification, because unlike the soluble iron compounds, it remains inert in the food and may 
contain more absorbable iron than an elemental iron source (175). The versatility of FePP and its 
acceptable sensory characteristics, owes to its popularity in fortifying sensitive food vehicles 
such as bouillon cubes, chocolate drinks and powders as well as infant cereals (176). The RBV 
of FePP has been reported to be in the range of 25-75% of FeSO4 (177,178), however strategies 
exist to improve the bioavailability of this compound.  
Particle size reduction is one employed strategy in increasing the bioavailability of 
insoluble iron compounds that are poorly absorbed (179,180). Wegmuller et al. used a 
hemoglobin-repletion animal model to assess the RBV’s of various sized micronized FePP 
fortificants (21µm, 2.5µm and 5µm) (181). They determined by reducing FePP from 21 µm to 
0.5 µm, micronized dispersable ferric pyrophosphate (MDFP) improved its bioavailability by 
almost 2-fold with a reported Hb comparison of 21.5 g/L to 43.7, respectively (181). Long-term 
efficacy studies have also demonstrated the effectiveness of MDFP consumption (182,183). In a 
32 week feeding trial with fortified margarine containing 14 mg micronized, ground FePP, 
Andersson et al. reported MGFePP improved SF and total body iron in young women (184). 
Although shown effective, the RBV of MDFP is primarily driven by the food matrix in which it 
is administered. A study investigated the influence two different food matrices (wheat-milk 
infant cereal and a rice meal) had on the overall RBV of MDFP with particle size 0.77 µm (185). 
Results indicated MDFP had an RBV of 62% when fortified in the infant cereal compared to 
only 15-25% RBV when consumed with the rice meal. This study demonstrated the importance 
food processing and food matrix has on the bioavailability of an iron fortificant. Currently, 
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chicken bouillon cubes are fortified with FePP, but a recent study reported its bioavailability to 
be only 4.4% when consumed as a broth, not as a complex meal (186).  Although iron absorption 
almost doubled (6%) with the addition of sodium pyrophosphate, the RBV was only 19%. 
 
Table 2.3. Key characteristics including Fe content, bioavailability and properties of iron 
compounds commonly used for food fortification.  
 
*Modified from Prentice et al (110).  
Natural iron compounds 
Industries are looking toward providing a “clean label” for their consumers. Although 
there is no clear definition of “clean label” by the FDA, more natural ways of providing iron as a 
fortificant are newly being explored (187). To date, research is scant in the realm of natural iron 
fortificants, with very few studied as potential candidates.   
A recent study by Sabatier et al (188) explored the IBA from a mutant yeast of 
Saccharomyces cerevisiae. This particular biomass in the mutant yeast was able to take up 
~0.9% iron (9 mg/g Fe). When the iron-enriched mutant yeast was fortified in a fresh cheese and 
fed to 16 female subjects, an RBV of 72% of FeSO4 was achieved (189). To our knowledge, this 
 
Iron Compounds 
 
 
Iron Content 
(%) 
 
RBV(%) 
 
Contribution to Changes in Sensory 
Properties 
Water soluble 
        Ferrous sulfate, 7H20 
        Ferrous sulfate, dried 
        Ferrous bisglycinate 
 
20 
33 
20 
 
100 
100 
>100 
 
Highly oxidative, causing rancidity 
Highly oxidative, causing rancidity 
Low induction of taste and color changes 
Acid soluble 
        Ferrous fumarate 
 
33 
 
100 
 
Low alterations to food matrix 
Insoluble  
        Elemental iron 
 
        Ferric pyrophosphate 
 
96-99 
 
25 
 
12-148 
 
21-74 
 
Variable characteristics of altering food 
matrix 
Low to no changes in organoleptic 
properties 
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is the only natural iron fortificant for which there is published data. Due to its low iron 
acquisition, there remains a concern of the overall efficacy this particular iron-enriched yeast has 
on long-term iron status improvements due to its low daily contribution.  
Aspergillus oryzae, otherwise known as koji, is a filamentous fungus that has been used 
for centuries to ferment soybeans and rice to make miso paste, sake, soy sauce, and other food 
products. It is structurally and fundamentally different than Aspergillus fumigatus otherwise 
known to cause detrimental health outcomes, especially those in which are immune-deprived. A. 
oryzae, has the capability of acquiring high amounts of iron, ~6-8%, and when grown in iron-
rich FeSO4 media, iron was found to be stored within the mycelia (190). Due to its strong 
capacity to sequester iron in media, A. oryzae was studied in humans as a supplement. Reddy et 
al saw a comparable iron absorption of the iron-enriched A. oryzae in FeSO4 rich media (ASP-s) 
compared to gold standard, FeSO4. Results from this study proposed further investigation into the 
capabilities of A. oryzae to be enriched in other iron-rich media, such as ferric pyrophosphate 
(ASP-p) due to its promising results in humans (191).  
The biological processes of iron acquisition in Aspergillus genus has been investigated. 
In A. fumigatus Haas et al. identified iron regulation processes whereby there is siderophore-
mediated iron storage as well as storage within the iron vacuole (192). If iron is stored within the 
vacuole, it may provide a protective barrier against when added to various foods (193). Because 
A. oryzae has the versatility to be enriched with different iron sources, this warrants further 
investigation on iron absorption of ASP-p as a fortificant in food vehicles compared to more 
commonly used iron fortificants, such as FePP.  
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Conclusion 
This literature review examined the resounding impact IDA has on our global population. 
Iron deficiency plays a significant role on the growth and development of women of child-
bearing age, infants and children and the consequences have been explained in this review. In 
addition, this review has explored the interface between dietary iron sources and the food 
matrices’ influence on iron absorption. This imposes a clear need to determine the most effective 
strategy towards providing regular consumption of sufficient, highly bioavailable iron sources to 
support iron maintenance. Food fortification appears to be the most cost-effective strategy but 
challenges remain in finding the most efficacious iron compound and vehicle for fortification. 
Due to this obstacle in iron fortification and the evolving public interest for more natural iron 
fortificants, this research was pursued to find a more iron bioavailable source for vehicle 
fortification to address global iron deficiency anemia.  
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CHAPTER 3: IRON ABSORPTION FROM A NOVEL IRON-ENRICHED FUNGAL 
FORTIFICANT IN YOUNG FEMALE SUBJECTS 
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Abstract 
Background: Fortification is a sustainable, cost-effective strategy in addressing global iron 
deficiency anemia. Iron compounds, such as ferrous sulfate (FeSO4) are highly absorbed, but 
interact with food matrices, whereas ferric pyrophosphate (FePP) does not react with food, but it 
has low absorption. The objective of this research was to compare iron absorption from 
Aspergillus oryzae enriched with FePP (ASP-p), FePP and FeSO4 by humans using a dual 
labelled staple isotope methodology. 
Methods: In two single blinded cross-over studies, healthy adult females with serum ferritin 
levels <40 g/L were randomized to consume a meal with rice, vegetable sauce and chicken 
bouillon fortified with iron. Subjects in study I (n=17, 18-35y) consumed a total of 4.2 mg of 
elemental iron from both iron sources as either 57FePP or 58ASP-p with natural abundance iron in 
each meal fed on 3 consecutive days. Similarly, in study II (n=18, 18-35y) subjects consumed 
57FeSO4 and 
58ASP-p. Iron absorption was measured using isotope enrichment in the whole 
blood 14 days following the final iron dosing. Hemoglobin, hematocrit, serum ferritin (SF) and 
serum C-reactive protein (CRP) were analyzed at baseline and at 14d.   
Results: Our results indicated the iron absorption from FePP:0.94% ± 0.43-2.03%; (geometric 
mean ± SD) was significantly (P<0.0001) lower than ASP-p:2.20% ± 1.00-4.83%, whereas in 
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Study II, ASP-p absorption of 2.98% ± 1.37-6.46% was significantly (P< 0.0001) lower than 
FeSO4: 9.89% ± 4.52-21.62%. After correcting the absorption values to serum ferritin of 15 
µg/L, ASP-p absorption was 2.6-fold higher than FePP and 72% lower than FeSO4. 
Conclusions: The higher iron absorption of ASP-p compared to currently used FePP, suggests its 
potential to be used in fortifying chicken bouillon. 
Keywords: iron absorption; stable iron isotope; iron fortification; ferrous sulfate; ferric 
pyrophosphate; Aspergillus oryzae 
Introduction 
Iron deficiency anemia (IDA) is the most prevalent nutrient deficiency, affecting 1.62 
billion people, globally (1). Iron deficiency is common among populations with high 
consumption of plant-based diets and higher rates of infections such as malaria (2,3). For 
instance, West and Central regions of Africa which are affected by the above factors, are also 
afflicted with the greatest incidence of anemia, with roughly 70% of the children having IDA 
(4,5).  Associated consequences of IDA include decreased cognitive function, productivity, and 
an increase in morbidity and mortality (6–9).  
Several strategies are implemented to address IDA including the use of supplementation 
with FeSO4; dietary modifications aimed at increasing daily iron intake; iron biofortification of 
staple foods (such as rice, flour and beans) (10); and iron fortification of foods. Despite 
improvements in iron status, supplements like FeSO4 are known to release a large bolus of iron 
into the gastrointestinal tract, leading to systemic inflammation and potential worsening of 
infections, like malaria. Dietary modifications are often unconventional due to the barriers in 
altering culturally adherent foods, especially in impoverished regions where there is a low 
accessibility to iron rich foods (11). Although staple food biofortification is the most sustainable 
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approach, fortifying affordable and widely-consumed food vehicles, such as condiments can also 
make a significant contribution in meeting daily iron requirements (12,13).  
There are numerous iron compounds available for food fortification, but not all are 
acceptable for many reasons. The challenges in fortification include finding a suitable iron 
compound with high iron bioavailability (IBA) while remaining inert in the food matrix. Soluble 
iron compounds such as FeSO4 and ferrous gluconate are highly absorbed, however they are also 
highly reactive in food, causing lipid oxidation and rancidity, among other adverse sensory 
outcomes (14). Elemental iron sources are ideal for fortification as they do not alter the 
organoleptic properties of the food; unfortunately, these are the least absorbed iron compounds 
(15).  FePP is widely used in foods sensitive to color changes and generally known to be 
absorbed at 21-74% compared to the standard of FeSO4 (14,16). Attempts have been made to 
improve iron absorption by reducing the particle size of FePP or through the addition of 
trisodium citrate during the rice extrusion process (17).   
Chicken bouillon cubes were selected as a candidate for fortification because of their 
regular consumption by many African countries. As already mentioned, FeSO4 is not suitable for 
bouillon fortification while FePP is commonly used. A recent study showed only 4.4% of the 
iron was absorbed from FePP when chicken bouillon cubes were dissolved in water and 
consumed as a drink, compared to 27% absorption from FeSO4 fortified cubes (18). The relative 
bioavailability of FePP is known to be influenced by the food matrix (19,16), therefore a lower 
iron absorption can be expected from FePP when consumed with a meal. This study’s results 
suggest the need to identify new iron sources for bouillon fortification.   
Recently, some studies focused on using yeast as natural iron fortificants (20,21)   
Although cheese fortified with yeast shows promising results, the amount of yeast needed to 
55 
 
 
achieve the required iron fortification would be higher because it  uptakes low amounts of iron 
(20,21).  A. oryzae is a filamentous fungus, otherwise known as koji, with a US FDA Generally 
Recognized as Safe (GRAS) status (22). It has been used for thousands of years to make 
fermented soy and rice products like sake, soy sauce, amazake, and miso paste (23,24). A. oryzae 
has the potential to be used as an iron fortificant due its unique ability to take up high amounts of 
iron (25). In a previous human study conducted by our team, A. oryzae grown in FeSO4 
containing media (ASP-s) showed similar absorption as FeSO4 when given with a semipurified 
meal., suggesting its potential as a new highly bioavailable source of iron for food fortification 
(manuscript in review). However, studies conducted with ASP-s showed slight color reaction in 
bouillon cubes.  To solve this problem Cura Global Health, Inc. developed another iron-enriched 
A. oryzae product, grown in FePP (ASP-p) (26).  Hence, the objective of this study was to 
investigate the effectiveness of the ASP-p iron absorption and compare it with commonly used 
fortificants FePP and FeSO4. 
Subject and Methods 
Subjects: Healthy, nonsmoking, females of 18-35 y, with ferritin < 40µg/L, but not anemic, were 
recruited for both iron isotope studies by sending a mass email to faculty and students at Iowa 
State University (ISU). These criteria were used because individuals in this category have a high 
risk for developing iron deficiency anemia (IDA) and an increased response to iron fortified 
foods due to low iron stores (27). Exclusion criteria included history of chronic or 
gastrointestinal conditions, in addition to having known food allergies to the ingredients in our 
administered test meal. Participants were excluded from the study if they were vegetarian, 
pregnant or lactating, or clinically classified as underweight (BMI <18.5 kg/m2) or overweight 
(BMI ≥ 25kg/m2). Participants were ineligible if they were taking any medications other than 
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oral contraceptives. Those consuming vitamin and/or mineral supplements were asked to 
discontinue their use at least two weeks prior and throughout the study period. Participants were 
not allowed to donate blood or plasma one month prior or while in the study.  All subjects 
formally agreed to participate and signed consent forms. The study was approved by the 
Institutional Review Board of Iowa State University. 
In study 1 comparing the absorption of FePP to ASP-p, a total of 58 subjects were 
screened, of which only 18 were eligible based on inclusion criteria. One subject dropped out of 
the study halfway through the feeding trial after becoming ill with the flu, therefore 17 subjects 
completed the study (Figure 1). In study II evaluating FeSO4 and ASP-p, 77 individuals were 
screened and 19 were eligible. Similarly, one subject dropped out midway through the study 
unable to finish eating the meal containing the iron treatment. Eighteen subjects participated in 
the final analyses for study II (Figure 1). Of the total 35 participants, 77% were White, 11.4 % 
Hispanic/Latino, 5.7% Asian, 2.9% African American and American Indian.  Both iron 
absorption studies required at least 16 participants to detect a 30% difference in iron absorption 
with 80% power at P<0.05 using previously reported standard deviation of 0.2 (within-subject) 
for absorption following log10 transformation (20). 
Stable Isotope Analysis: Stable isotopes (57Fe and 58Fe) were purchased from Chemgas 
(Boulogne, France) and shipped directly to Dr. Paul Lohmann® (Emmerthal, Germany) for 
labelling 57FePP, 57FeSO4, and 
58FePP using their commercial preparation for iron salts. Iron 
salts with natural abundance iron were made by the same company using similar methodology.  
Iron content and enrichment of compounds were as follows: [57Fe]-FePP (26.4% Fe with 95.8% 
enrichment), [57Fe]-FeSO4 (35.95% Fe with 95.3% enrichment) and unlabeled, naturally 
abundant FePP containing 22.3% Fe and FeSO4 with 37.0% Fe. 
58FePP was used to intrinsically 
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label A. oryzae to make 58ASP-p.  Methodology for intrinsically labelled 58ASP was based on our 
previous study (21)C Briefly, A. oryzae was grown in the presence of 58FePP, the intrinsically 
labelled 58ASP compound was then harvested, oven dried, and ground to 100 mesh-size powder, 
under food grade conditions. The 58ASP powder contained 5.0% iron with 99.5% 58Fe 
enrichment, as measured by Magnetic Sector Thermal Ionization Mass Spectrometry at Cornell 
University. Inductively Coupled Mass Spectrometry was used to measure iron content in all iron 
sources. Unenriched A. oryzae (Ao) and enriched ASP-p with natural abundance iron contained 
0.5 mg/g and 87.9 mg/g of iron, respectively. The Ao was used to match the fungi content of 
ASP-p in all other test meals.  
Test Meal: The test meal composition used to feed the stable isotopes was modified based on a 
previous study (19). The meal was formulated to contain low elemental iron and low amounts of 
iron absorption inhibitors and enhancers. Each meal consisted of 42g of each zucchini, carrots, 
green cabbage, and 24g yellow onion, 6.3g corn oil (Mazola®, ACH Food Companies, Inc., 
Cordova, TN), 6.6g Maggi’s unenriched granulated chicken flavor bouillon (Nestlé USA, Inc., 
Glendale, CA), and 75g dry weight unenriched, medium-grain 80% jasmine, 20% white rice 
blend (Three Elephant Brand, AAA Grade, Thailand). Total iron content was measured in both 
chicken bouillon and jasmine rice using Inductively Coupled Mass Spectrometry and shown to 
contain 0.56 mg Fe together per test meal. Thirteen servings of each vegetable (546 g of each 
zucchini, cabbage, carrot, and 312 g onion) were diced, added to 234 g nanopure water in an 
instant 6-quart pressure cooker (Power Pressure Cooker XL, Inc., Tristar Products), cooked for 
14 minutes at 109C and allowed to cool for one hour. Following cooling, vegetables were 
pureed and corn oil was added to make a sauce that was stored at -20C until feedings. The day 
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preceding our served meal, jasmine rice was prepared at 2:1 water to rice ratio and 200g cooked 
rice was pre-portioned for the following day. Chicken bouillon was weighed in individual one-
ounce cups and all iron treatments (tracers and natural abundance) were meticulously added on 
top of the bouillon to prevent any isotopic loss. On the day of the feeding, the rice and vegetable 
sauce were individually heated thoroughly in a microwave, combined, and mixed with the 
chicken bouillon containing the respective iron tracers. The cups were rinsed three times with 
purified water to ensure all residual isotope was added to the meal. All the ingredients were 
mixed very carefully prior to serving.  
 
Fortification and Labelling of Test Meals: Two test meals were fed in both studies, referred to 
as A and B in study1; C and D in study 2. All test meals were designed to contain equal amounts 
of added iron (4.2 mg Fe). Rationale for the addition of iron is based on current iron fortified 
chicken bouillon; 3.3 g bouillon with 2.1 mg Fe/ meal or 6.6 g bouillon with 4.2 mg Fe/d. Test 
meals contained a total of 4.76 mg Fe, including the iron from the bouillon and rice. Meal A 
contained 3.34 mg 57Fe from 57FePP, 0.87 mg natural abundance iron from FePP. Meal B 
contained 0.68 mg 58 Fe from 58ASP-p and 3.52 mg as FePPAo (A. oryzae in FePP with natural 
abundance iron).  Meal C contained 4.2 mg of 57Fe from 57FeSO4 plus the matching 3.52 mg Ao 
that was in the labelled ASP.  Study I provided a total of 10 mg of 57Fe and 2 mg of 58Fe.  
Because of the low absorption values in the first study, we fed 12.5 mg 57Fe and 3 mg 58Fe total 
in the second study to ensure enough enrichment. 
 
Study Designs: In two controlled, single-blinded, cross-over study designs, participants were 
randomized separately in each study (using the “RAND” function in Excel).  In study I, people 
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consume both meal A (57FePP) and meal B (58ASP-p). The entire stable iron isotope dose (10.02 
mg of 57Fe or 2.04 mg 58Fe) was fed to each subject in 3 consecutive mornings meals. In Study 
II, people were randomized similarly to consume meal C (57FeSO4) and meal D (58ASP) and 
followed the same feeding protocol except with a few modifications as described below. 
 On day one of the study, participants were required to complete a 10 hour overnight fast 
prior to consuming the first test meal between the hours of 6:00 and 8:30 am at our Nutrition and 
Wellness Research Center (NWRC) at ISU. Baseline blood was drawn by a phlebotomist and 
followed by administration of the isotopes in either meal A, B, C or D. Participants were 
instructed to consume the entire meal within 15 minutes and bowls and spoons were rinsed with 
filtered bottled water for minimum three times or until all food residue was gone. Water was 
ingested after each rinse and bowls and spoons were checked by research personnel to confirm 
all isotope was consumed. Subjects were not allowed to eat or drink for an additional 3 h, except 
water. Fourteen days after the last test meal was eaten, participants’ 10 h fasted blood was drawn 
for final hemoglobin and iron enrichment analyses.   
The difference between study I and II were the alterations in feeding days to 
accommodate the students’ 3 hour availability during the weekday with classes. Isotopes were 
still fed in three morning meals but over two consecutive weekends (Friday, Saturday and 
Sunday).  
 
Blood analysis: Serum and whole blood were collected at screening and stored (-20C) until 
time of measurement. Serum ferritin concentrations (S-22 Spectro Ferritin kit Ramco 
Laboratories, Inc., Stafford, TX) were assessed to determine participant eligibility (<40 ug/L) as 
well as at baseline and endpoint whole blood was sent to a Certified Diagnostic Laboratory 
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(Quest Diagnostics, Lenexa, KS) for blood chemistry analysis, including hemoglobin and iron 
status markers. Baseline and final serum were collected from participants and stored at -20C 
until further analysis were performed for serum ferritin and serum C-reactive protein (CRP 
ELISA, American Laboratory Products Company, Salem, NH). Final whole blood samples 
(frozen) were sent to ETH Zürich (Zürich, Switzerland) for fractional stable isotope enrichment 
analysis.  
 
Enrichment Calculations: Iron from the whole blood samples was extracted by the anion 
exchange chromatography method (28). The amounts of 57Fe, 58Fe isotopic labels in blood 14d 
after the second meal feeding was assessed on the basis of the shift in iron-isotope ratios and the 
estimated amount of iron circulating in the body. Circulating iron was calculated on the basis of 
blood volume estimated height, weight (29) and Hb concentrations. Fractional iron absorption 
was calculated on the assumption that 80% is incorporated into hemoglobin (30). Isotope 
measurements were performed using a negative thermal ionization –mass spectrometry.  
 
Statistical analysis: All statistical analyses were performed by GraphPad Prism 6.07 software 
(GraphPad Sotftware, Inc., San Diego, CA). Normally distributed data were presented as means 
 SDs. Non-normally distributed data were log transformed prior to statistical analysis; values 
were presented as geometric means  SDs for iron absorption, ferritin, and CRP values. Student 
t-test was used to compare the absorption of ASP-p with FePP to ferrous sulfate. There was an 
outlier was identified with absorption with Asp-p in the study and statistical analysis was 
performed with and without using the subject. Pearson correlation analyses were performed 
between absorption. To be able to combine two studies, we corrected absorption to a serum 
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ferritin of 15µg/L as described by Cook et al (31) and analyzed mean differences among groups 
using a one-way ANOVA followed by Tukey’s multiple comparison test. All differences were 
considered significant at P 0.05.  
Results 
Subject Characteristics: General baseline anthropometric and biochemical characteristics of 
subjects in both study I and II are presented in Table 1. Mean age of participants in Study I and 
Study II were 20 y and 21 y, respectively. Average BMI of 22.1 kg/m2 and 22.2 kg/m2 for study I 
and II, respectively, were within normal range (18.5-24.9 kg/m2). At screening, all participants in 
both studies had hemoglobin levels within normal levels (>12 g/dL) according to the reference 
values provided by the diagnostic lab (Quest DiagnosticsTM). The mean ±1SD hemoglobin in 
study 1 (12.8 ±1.4 g/dL) was similar to study II (12.9 ±0.7 g/dL). One subject in study I had 
elevated baseline (at the beginning of the study) serum ferritin (74.7ug/L), but met the inclusion 
criteria with a screening SF (33.1 ug/L). This subject’s baseline CRP concentration was not 
elevated (<5 mg/L) but did show trends in increasing ferritin throughout the study indicated by a 
final SF of 97.5 ug/L. In study II, one reported to have high baseline SF (56.2 µg/L), however 
ferritin at screening was 4.9 ug/L and final value was 11.4 ug/L with no elevated CRP, another 
study II subject did have an elevated baseline CRP concentration (8.073 mg/L), but all SF 
concentrations remained within range. Geometric means of serum ferritin were comparable to 
study I with 15.4 ±13.0 ug/L and 18.2 ±18.0 ug/L and not significantly different between two 
studies. None of the other characteristics were significantly different between two studies.  
 
Iron absorption: Fractional iron absorption values are presented as geometric means ± SD in 
Figure 2. Ferric pyrophosphate absorption was low (0.94% ± 0.10-3.52%) and ASP was 
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significantly (P<0.0001) higher by 2.3-fold (2.20% ± 0.26-7.34%; Figure 2A) than FePP. The 
mean FeSO4 and ASP percentages of absorptions were 9.89% (SD± 1.95-28.94%) and 2.98% 
(SD± 0.94-19.29%), respectively (Figure 2B). The 70% lower absorption of ASP compared to 
FeSO4 was statistically (P<0001) different (Figure 2B). One outlier was identified in the ASP 
group with similar absorption as FeSO4, but the study outcome did not change leaving the 
subject in the analysis and the difference remained significant (P<0.0002).   Highly significant 
correlations were found between FePP and ASP-p (r=0.92, P<0001) in study I and FeSO4 and 
ASP-p (r=0.537, P<0.03) in study II. When we combined the two studies by correcting 
individual absorption values to a serum ferritin of 15 µg/L (Figure 2C), the RBV compared to 
FeSO4, of ASP-p was 28% and FePP was 11% which were statistically different from each other 
(P<0.001) as well with FeSO4 (P<0.0001) 
Discussion 
Iron fortification is a cost-effective strategy towards reducing the incidence of iron 
deficiency anemia. It is technically difficult to fortify with highly bioavailable iron salts, such as 
ferrous sulfate, due to unacceptable flavors and colors with the food matrix. Insoluble iron 
compounds are less reactive with food, however they have low bioavailability. Several iron 
compounds have been identified to provide higher bioavailable iron without altering the 
organoleptic properties (16). Because of higher bioavailability (greater than FeSO4) of 
NaFeEDTA, it’s been long used to fortify soy and fish sauce, but the high cost to produce 
NaFeEDTA prohibits its use (32). Additionally, the iron bound EDTA moiety has shown to 
slowdown the fermentation process of yeast, hindering its use in grain products such as bread 
(33) as well as showing signs of rancidity following sensory reports from industries (34). 
Another water-soluble iron compound, bis-glycinate, used in fortification reported to 
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immediately precipitate upon incorporation into soy sauce potentially causing lipid peroxidation 
(35).  
Because of gaining interest in clean label of food products (36), use of natural iron 
sources may be promising in food fortification, but to date, there is limited research in this area. 
A recent study (20) that examined the iron absorption of iron-enriched brewer’s yeast, 
Saccromyces cervisea reported a 72% of RBV in humans when fed with cheese. Although the 
results of the above study look promising, the mutant yeast strain was shown to acquire only 
~0.9% iron, necessitating a substantial amount of the yeast to be added in food products to meet 
daily iron needs. A. oryzae acquires high levels of iron when grown in iron-rich media at a level 
of 8-10% (Wicking patent). Although not much data exist on the iron metabolism in A. oryzae, 
other Aspergillus species and yeast known to acquire iron and store in the vacuoles, may be as 
polyphosphate or iron oxide forms (37).  We can speculate a similar type of iron acquisition and 
storage in A. oryzae.  
The aim of the current study was to determine whether iron absorption from ASP-p is 
greater than FePP, which is currently used for fortifying chicken bouillon. Chicken bouillon 
cubes are widely distributed (38) in Africa by multinational corporations and since it is a 
frequently consumed condiment by all age groups in Africa, with reports indicating weekly 
consumption as 96% across Cameroon households (39). Similarly, 97% of the respondents 
consumed bouillon cubes with a mean intake 3.7 g/d in women of childbearing age (40) and may 
be around 4.3-8.6 g/d in Senegal rural and urban areas, respectively.  
Most of the chicken bouillon cubes are fortified with FePP because it causes minimal 
organoleptic problems and known to have RBV of 50% of ferrous sulfate (41). Since bouillon 
cubes are generally fortified with 0.6 mg Fe/g of bouillon, we used the same iron to bouillon 
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ratio (4.2 mg Fe/6.6g bouillon). Our study showed that FePP absorption is very low (around 1%) 
when consumed with a rice meal,and only 11% of FeSO4 absorption when absorption values 
were corrected to ferritin of 15 µg/L. The iron absorption value in our study is four times lower 
than a previous study showing a 4.4% FePP absorption from bouillon cubes.  The latter might be 
due to lower iron status of the subjects (9.4 µg/L) and/o lack of meal inhibition, since the 
bouillon cubes were given in a water-based  drink rather than with food (18). Despite the 
differences in absorption values between two studies, the RBV of 11% in our study is 
comparable to the 13% reported by Cercamondi, et al., . Theseresearchers attempted to increase 
the absorption of FePP by adding sodium pyrophosphate which improved it by 46% (6.4%), but 
the RBV was still 19% (19). With the daily consumption of 4 g bouillon, the authors pointed out 
that women of child bearing age can meet 11% of their requirement (0.9 mg). However, meeting 
the daily iron requirements will be much lower, since the absorption will be dampened with the 
meal because of the iron interaction with the food components that has been shown previously 
(42).  
Thus, finding an alternative iron fortificant with higher bioavailability but less reactivity 
than FeSO4, will be advantageous for the individuals who consume lower amounts of bouillon in 
meeting meaningful daily iron requirements to improve iron status. To our knowledge, no 
current research has examined iron absorption from an iron-enriched fungal fortificant. Since 
iron may be stored in the vacuole, it may create a barrier between the food matrix and iron, 
thereby reducing rancidity, discoloration and taste change. Absorption of ASP-p was 2.3-fold 
higher than currently used FePP, suggesting it might be an effective fortificant in bouillon cubes. 
The RBV of ASP-p in our study was 28%, which is higher than the 19% reported with combined 
NaPP and FePP treatment. (19).  
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In our previous study a RBV of 78% (21) was shown with ASP-s, but a comparison 
cannot be made with the current study because in that study we provided the treatment with a 
semipurified liquid meal. As it was explained before, meal effect on bioavailability of iron is an 
important factor.  Absorption of FeSO4 is generally used to assess RBV of iron compounds but 
caution should be taken as RBV can vary based on the meal type and the iron status. The RBV of 
micronized dispersible FePP was reported to vary from 15-62% depending on the food matrix 
(19).  
Since women of child-bearing age require 1.46 mg Fe/day based on 10% absorption (43) 
we estimated that the current iron fortification levels in bouillon cubes are not sufficient. If 
women consume 6.6 g of bouillon fortified with 4.2 mg Fe, they can only meet 3.4% of daily 
requirement with FePP.  Fortification with ASP-p provides 8.2% of iron requirement as, almost 3 
times iron than FePP (2.9% vs 1.1 % for ASP-p and FePP, respectively). However, since the 6.6 
g we used in our study exceeds the average reported consumption of 1-4g bouillon/day, with 4 g 
consumption of bouillon will provide only 5% of the requirement. Therefore, considerations 
should be made in increasing the amount of iron to 5 mg instead of 2.5 mg per 4 g of bouillon in 
order to meet 10.3% daily requirement for women of child-bearing age instead of promoting 
higher amounts of bouillon cube consumption with high sodium content. In conclusion, meeting 
10% of daily iron requirement through condiment fortification is a significant additional source 
of iron. The results of our study suggest that ASP-p is a promising, natural iron fortificant that 
may be used various food vehicles to improve iron status of the population who are vulnerable 
for iron deficiency anemia.  
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Table 3.1. General baseline characteristics and iron status indicators of all subjects1  
                                      Study I (n=17) Study II (n=18) 
 
Age, y 
 
20.1 + 2.4 (18-26) 
 
21.3 + 2.7 (18-29) 
 
Weight, kg 61.5 + 6.3 (50.2-70.8) 62.2 + 5.3 (49.6-71.3) 
 
BMI, kg/m2 22.1 + 1.7 (18.8-24.6) 22.2 + 1.2 (19.6-24.1) 
 
Hemoglobin, g/dL 12.8 + 1.4 (10.4-15.4) 12.9 + 0.7 (11.7-14.3) 
 
Hematocrit, % 38.3 + 3.6 (32.2-45.1) 
 
38.0 + 2.0 (35.5-42.5) 
 
Serum CRP,2 mg/L 0.41 + 1.7 (0.002-5.16) 0.63 + 2.2 (0.004-8.07) 
 
Serum ferritin,2 µg/L 18.2 + 18.0 (4.9-79.5) 15.4 + 13.0 (6.5-56.2) 
 
1Values are means + SD; (range). BMI, Body mass index; CRP, C-reactive protein 
2Geometric means + SD; (range)  
No significant differences in the listed variables were found between two studies 
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Figure 3.1. Study Design and eligibility; Study I and II presented. Participants were recruited 
based on eligibility from HSQ, health screen questionnaire including BMI 18.5 to 25.0 kg/m2. 
Subjects had follow-up assessments for serum ferritin (<40 µg/L) and hemoglobin concentrations 
(age-dependency from Quest Diagnostics). Flowchart indicates test meal AB, BA in a crossover 
design. Isotopes were given to each subject over 3 test meals. Study I subject withdrew due to 
flu; study II subject withdrew from unfinished test meal.    
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Figure 3.2.  Iron absorption plot of 57FePP (triangle),58ASP (square), and 57FeSO4 (circle). for 
study I (n=17) and study II (n=18) in Figures 2A and 2B. 58ASP were significantly different 
(P<0.01); 58ASP was statistically significant from 57FeSO4. ASP was significantly higher than 
FePP (P<0.01) and lower than FeSO4. Values were significant at P<0.05 (paired t-test).  
 
A 
B 
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Figure 3.3. Mean iron absorption plots of FeSO4, FePP and ASP-p combined absorptions after 
corrected to a SF of 15 µg/L. RBV of ASP-p compared to FeSO4, was statistically different from 
each other (P<0.001) as well with FeSO4 (P<0.0001). Values were significant at P<0.05 (one-
way ANOVA followed by Tukey’s multiple comparisons test.  
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CHAPTER 4: GENERAL CONCLUSIONS 
 
The research presented in this thesis investigated the iron absorption from three iron 
fortificants, of which one was a new, novel iron-enriched A. oryzae (ASP-p). Findings from this 
study demonstrated the highest absorption from FeSO4, however we know from the literature 
that FeSO4 is unsuitable for fortification as it alters the taste, color and shelf-life properties when 
added to food. Results from this study illustrated a higher iron absorption from ASP-p (28% 
RBV) than currently used, FePP (11% RBV). Although this finding of 28% RBV is the highest 
among those investigated in chicken bouillon, it does not provide sufficient amount of iron to 
meet daily requirements in women and children. 
Based on our findings, we acknowledge chicken bouillon may not be the most effective 
vehicle for iron fortification due to the inhibiting dietary components in the condiment. 
Therefore, future research is warranted in finding a more widely consumed vehicle or through 
new technologies towards enhancing the iron bioavailability from cost-efficient iron compounds.  
Future ideas are based on our team’s previous work assessing iron-enriched Aspergillus 
oryzae as a supplement (ASP-s). In a human study, ASP-s demonstrated to be as bioavailable as 
FeSO4. Because ASP-s cannot be added directly to the food, (as it results in food discoloration) 
future research aims would include investigation of the addition of sodium pyrophosphate 
(NaPP) to the ASP-s. NaPP would act as a protective compound by decreasing the ability of 
ASP-s to oxidize the food, ultimately reducing the organoleptic properties it exerts. If this is 
plausible, sensory studies and bioavailability through in vitro models are the first step towards 
assessing the outcomes of ASP-s plus NaPP in fortification.   
 
75 
 
 
APPENDIX: IRB APPROVAL  
 
